Home Page 1

Reference URL

Comment

Save to favorites

To link to the entire object, paste this link in email, IM or document

To embed the entire object, paste this HTML in website

To link to this page, paste this link in email, IM or document

To embed this page, paste this HTML in website

The effect of using fibrates in conjunction with statins for the management of dyslipidemia in persons with Type II diabetes mellitus

Page 1

Save page

1 of 157

View Description

View PDF & Text

Download

small (250x250 max)

medium (500x500 max)

large ( > 500x500)

Full Resolution

All (PDF)

This page

All

Subset

PDF
Text

Text Search...

Object Description

Title	The effect of using fibrates in conjunction with statins for the management of dyslipidemia in persons with Type II diabetes mellitus
Author	Suh, Hae Sun
Author email	haesuh@usc.edu; haesun.suh@gmail.com
Degree	Doctor of Philosophy
Document type	Dissertation
Degree program	Pharmaceutical Economics & Policy
School	School of Pharmacy
Date defended/completed	2009-05-05
Date submitted	2009
Restricted until	Unrestricted
Date published	2009-08-06
Advisor (committee chair)	Doctor, Jason N.
Advisor (committee member)	Hay, Joel W. Hsiao, Cheng
Abstract	OBJECTIVES: To examine the effect of a statin plus fibrate combination therapy versus a statin monotherapy on the occurrence of cardiovascular disease (CVD) in subjects with type II diabetes in a managed care setting.; METHODS: “Combo-group” - defined as subjects who used a statin less than six-months and augmented to a statin plus fibrate for more than six-months - and “mono-group” - defined as subjects who used a statin less than six-months and remained on the statin for more than six-months - were identified among subjects with type II diabetes with a two-year intake period (7/1/2002-6/30/2004) and a three-year follow-up using administrative claims from a West-coast based health plan in the US covering a population of four million. Outcomes were identified as any occurrence of CVD which included ischemic heart disease, cerebrovascular disease, and peripheral vascular disease. A univariate probit model was developed to evaluate adjusted CVD-risk. Since this was a retrospective database analysis, we suspected an endogeneity issue in regards to the treatment indicator variable. To control for the potentially endogenous treatment variable, we built a two-stage probit model that used an instrumental variable method using two-stage residual inclusion estimation. We also used the two-stage least squares (two-stage predictor substitution method) model and the bivariate probit model.; We used physician prescribing preference as the instrumental variable. To test the validity of the instrument, we tested for the correlation between the instrument and treatment indicator using a standard t-test. To check whether it is valid to exclude the instrument from the main equation, a Wald test was performed. The Stock and Yogo test was used to check the weak instrument issue. To test the endogeneity of the treatment indicator, we performed a Hausman test.; RESULTS: Mean (±SD) age was 58 (±11) years in the combo-group (N = 318) and 61 (±11) years in the mono-group (N = 9,928). In the combo-group, mean (±SD) treatment-duration was 296 (±347) days for the statin plus fibrate therapy following 118 (±52) days for the statin-monotherapy. In the mono-group, mean (±SD) treatment-duration was 554 (±413) days for the statin-monotherapy following 115 (±51) days for the statin-monotherapy. The proportion of CVD occurrence between groups were not significantly different (combo-group vs. statin mono-group, P = 0.522). Adjusting for age, gender, prior CVD, CVD-related pharmacy-costs, Elixhauser-comorbidity, and diabetes with complication, the combo-group experienced 6.5% less CVD than the mono-group on average (P = 0.009). All covariates were significantly associated with the occurrence of CVD. For the instrumental variable model to address endogeneity, specification tests indicated that the validity of the instrument was satisfied and there was not a weak instrument problem. However, the Hausman test implied that the treatment indicator was not endogenous (P = 0.647).; CONCLUSIONS: In a managed care population with type II diabetes after adjusting for known baseline differences, the occurrence of CVD was significantly lower among subjects who augmented the short-term statin use with the statin and fibrate combination therapy compared with those who remained on the statin monotherapy. Our failure to identify “selection effects” (endogeneity issue) may be due to the strength of the instrument and the untestable assumptions.; POLICY IMPLICATIONS: People with diabetes die of CVD at rates 2-4 times higher than subjects without diabetes. Managing diabetic dyslipidemia (elevated low-density lipoprotein, decreased high-density lipoprotein, and elevated triglycerides) is regarded as one of the effective strategies to reduce the risk of CVD. We hope this result will be useful in health policy to find effective treatment strategies to reduce the risk of CVD in diabetics.
Keyword	statin; fibrate; observational study; cardiovascular disease; diabetic dyslipidemia; instrumental variable; selection bias
Language	English
Part of collection	University of Southern California dissertations and theses
Publisher (of the original version)	University of Southern California
Place of publication (of the original version)	Los Angeles, California
Publisher (of the digital version)	University of Southern California. Libraries
Provenance	Electronically uploaded by the author
Type	texts
Legacy record ID	usctheses-m2519
Rights	Suh, Hae Sun
Repository name	Libraries, University of Southern California
Repository address	Los Angeles, California
Repository email	http://www.usc.edu/isd/libraries/services/ask_a_librarian/email/
Filename	etd-SUH-2955
Archival file	uscthesesreloadpub_Volume40/etd-SUH-2955.pdf